Date of Submission
Project Advisor 1
One of the most important platinum-based drugs to have been used for chemotherapeutic purposes is cis-diamminedichloroplatinum(II) or cisplatin. The selective cytotoxicity of cisplatin has been determined to be mainly due to cross linking of interstrand guanosine residues and intrastrand d(GpG) regions in duplex DNA. The DNA-cisplatin adduct formation has been shown to inhibit DNA replication and chain elongation, which eventually triggers cell apoptosis. NAMI-A is a ruthenium-based chemotherapeutic drug that has lower cytotoxicity and increased specificity to inhibiting metastasis. Using cisplatin and NAMI-A as model drugs, a novel platinum-ruthenium based potential chemotherapeutic compound IT127 has been synthesized. Recent studies have shown that treatment of plasmid DNA with IT127 has greater effect on DNA mobility and replication inhibition than cisplatin. The aim of this research was to study binding specificity IT127 to single-stranded DNA and to compare the results to cisplatin-treated DNA. Results confirmed the preference of cisplatin for oligo(dG) sites, while IT127 showed lower DNA binding specificity.
Access restricted to On-Campus only
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Ganguly, Prabarna, "Binding Specificity of Platinum-Ruthenium Based Drugs to DNA" (2013). Senior Projects Spring 2013. 243.